382TiP - CONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)
| Autor: | Tolaney, S.M., Blum, J.L., Bondarenko, I., Chan, A., DaCosta, N., Feng, Y.-H., Izarzugaza, Y., Kim, S.-B., Liu, M.-C., Oliveira, M., Ow, S.G.W., Pavic, M., Peréz Lopéz, M.E., Rugo, H.S., Schwartzberg, L., Stradella, A., Kroll, S., O’Connell, J., Wei, T., Mittendorf, E.A. |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v138-v139 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|